Femasys (FEMY)
(Delayed Data from NSDQ)
$1.17 USD
+0.05 (4.46%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $1.19 +0.02 (1.71%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
FEMY 1.17 +0.05(4.46%)
Will FEMY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for FEMY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FEMY
Femasys Stock Rises After FDA Clearance for FemChec Diagnostic Device
Femasys Shares Rise on CE Mark & Canada Approval for FemVue MINI
FEMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates
Omega Therapeutics, Inc. (OMGA) Reports Q2 Loss, Tops Revenue Estimates
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates
Other News for FEMY
Femasys Announces Infertility Clinic Customers from Coast to Coast
Femasys announes infertility clinic customers from coast to coast
Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed? for over $1.3M in Spanish Market
Femasys secures partnerships for commercialization of Femaseed and FemVue
Femasys secures distribution partnerships for commercialization of FemaSeed